Roxana Dronca, MD
Medical Oncology · Jacksonville, FLNPI 1982657052
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $45,567 of the $52,015 with a category attached, or 87.6%. 10 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 50.9% of the total.
Across 33 payments — averaging $1576.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$26K
- Regeneron$10K
- Sanofi$6K
- Immunocore Limited$4K
- EMD Serono, Inc.$4K
- Eisai Inc.$2K
- plus $225 from 4 others
Across 63 payments — averaging $19,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1M
- Alkermes, Inc.$158K
- Regeneron$63K
What the payments were for
- Consulting fees$45,56788%
- Speaking & faculty fees$3,2006%
- Travel & lodging$2,3955%
- Food & beverage$8532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $26,494 |
| Regeneron | 10 | $9,756 |
| Sanofi | 3 | $6,224 |
| Immunocore Limited | 6 | $3,916 |
| EMD Serono, Inc. | 1 | $3,880 |
| Eisai Inc. | 1 | $1,520 |
| Iovance Biotherapeutics, Inc. | 1 | $137 |
| Array Biopharma Inc | 2 | $53 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,015 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Jacksonville
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.